ResMed, Inspire Medical Shares Down After Eli Lilly Provides Sleep Apnea Study Update
By Josh Beckerman
Shares of ResMed, a breathing technology company, fell after Eli Lilly said its weight-loss drug tirzepatide reduced the severity of sleep apnea in Phase 3 trials.
RedMed's shares dropped the most in 10 months on Monday, retreating 11% to $182.73 in early afternoon trading. The stock has declined 15% in the last 52 weeks.
Citi downgraded breathing technology company ResMed to neutral from buy on Monday.
Needham said in a research note that Lilly's results were in line with its expectations. "Given the relatively modest near-term headwind we expect through FY27, we view today's weakness as a buying opportunity" for ResMed shares.
Meanwhile, shares of Inspire Medical Systems, which provides technology for sleep apnea, were down 15% to $138.17. Stifel Financial reduced its target price for Inspire to $170 from $210 and maintained its hold rating.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 24, 2024 13:43 ET (17:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations